XOMA Corporation (XOMA)
Stock Price:
$18.11 USD
1.69 (10.29%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $18.00 -0.11 (-0.61%) Aug 12, 5:26 PM
Key Info
| Market Cap |
199.54M |
| Revenue (ttm) |
10.53M |
| Net Income (ttm) |
-9.43M |
| Shares Out |
11.02M |
| EPS (ttm) |
-0.99 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$18.11 |
| Previous Close |
$16.42 |
| Change ($) |
1.69 |
| Change (%) |
10.29% |
| Day's Open |
16.55 |
| Day's Range |
16.45 - 18.27 |
| Day's Volume |
35,579 |
| 52-Week Range |
14.14 - 28.85 |
More Stats
| Market Cap |
199.54M |
| Enterprise Value |
181.63M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
11.02M |
| Float |
6.39M |
| EPS (basic) |
-1 |
| EPS (diluted) |
-0.99 |
| FCF / Share |
-1.71 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
543,679 |
| Short Ratio |
14.72 |
| Short % of Float |
8.57% |
| Beta |
1.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
18.96 |
| PB Ratio |
4.40 |
| Revenue |
10.53M |
| Operating Income |
-9.88M |
| Net Income |
-9.43M |
| Free Cash Flow |
-18.50M |
| Net Cash |
17.91M |
| Net Cash / Share |
1.63 |
| Gross Margin |
162.63% |
| Operating Margin |
-93.84% |
| Profit Margin |
-93.00% |
| FCF Margin |
-175.76% |
| ROA |
-6.75% |
| ROE |
-31.77% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.50*
(62.89% upside)
Low
29.0
Current: $18.11
High
30.0
Target: 29.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 18.37 | 5.30 | 52.69 | 5.56 | 55.45 | 18.87 | 35.45 | 33.78 | 58.20 | 33.64 |
| Revenue Growth | 246.67% | -89.94% | 846.98% | -89.97% | 193.9% | -46.78% | 4.94% | -41.95% | 72.99% | - |
| Gross Profit | 18.37 | 5.30 | 52.69 | 5.56 | 55.45 | 18.87 | 35.45 | 33.78 | 58.20 | 33.64 |
| Operating Income | -3.89 | -16.86 | 17.03 | -61.56 | -39.72 | -81.83 | -58.21 | -56.62 | -33.96 | -67.10 |
| Net Income | -1.98 | -13.34 | 14.60 | -53.53 | -20.61 | -38.30 | -124 | -71.07 | -32.74 | -68.76 |
| Shares Outstanding | 8.76 | 8.37 | 7.62 | 6.02 | 5.89 | 5.37 | 4.35 | 3.23 | 1.58 | 0.93 |
| Earnings Per Share | -0.23 | -1.59 | 0.73 | -8.89 | -3.50 | -13.49 | -28.60 | -22.00 | -20.80 | -73.80 |
| Operating Cash Flow | -0.29 | -12.64 | 2.69 | -33.69 | -30.89 | -78.28 | -45.92 | -40.77 | -29.06 | -52.54 |
| Capital Expenditures | -19.30 | -15.01 | 1.61 | -0.01 | -0.41 | -0.33 | -1.17 | -2.05 | -3.30 | -0.34 |
| Free Cash Flow | -19.59 | -27.65 | 4.29 | -33.70 | -31.30 | -78.61 | -47.08 | -42.81 | -32.37 | -52.88 |
| Cash & Equivalents | 56.69 | 45.78 | 43.47 | 25.74 | 66.26 | 78.45 | 122 | 85.33 | 48.34 | 37.30 |
| Total Debt | 32.85 | 22.48 | 14.57 | 43.17 | 48.67 | 35.31 | 40.99 | 41.04 | 36.32 | 13.69 |
| Net Cash / Debt | 23.84 | 23.30 | 28.90 | -17.43 | 17.60 | 43.14 | 80.66 | 44.29 | 12.02 | 23.61 |
| Assets | 95.72 | 63.79 | 44.94 | 28.68 | 74.88 | 89.40 | 135 | 106 | 78.04 | 74.25 |
| Liabilities | 51.74 | 45.00 | 39.15 | 75.89 | 77.19 | 86.30 | 139 | 84.21 | 63.03 | 50.66 |
| Book Value | 43.99 | 18.79 | 5.79 | -47.21 | -2.31 | 3.10 | -3.99 | 21.47 | 15.01 | 23.59 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
XOMA Corporation |
| Country |
United States |
| Employees |
11 |
| CEO |
James R. Neal |
Stock Information
| Ticker Symbol |
XOMA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: XOMA |
Description
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.